19 completed, 5 unknown, 4 active not recruiting, 4 recruiting. 36 Phase 1, 10 Phase 2.
Follow Frontotemporal Lobar Degeneration: new trials by email Literature Review of Frontotemporal Lobar Degeneration trials Research Report on Frontotemporal Lobar Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MSC-Exosome Therapy for Frontotemporal Dementia Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes （Low-Dose）, Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes （High-Dose）, Placebo Comparator (0.9% NaCl) - Frontotemporal Dementia | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 33 | 2026-07-01 | 2026-07-13 |
| AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980) AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg - Alzheimer Disease, Preclinical Alzheimer's Disease | Phase 1 | Recruiting | Institute for Molecular Medicine | 48 | 2026-06-23 | 2026-08-21 |
| Study in Asymptomatic GRN-FTD Patients to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 VES001 - Dementia, Frontotemporal Dementia | Phase 1 | Completed | Mads Kjolby | 6 | 2024-12-12 | 2025-08-24 |
| A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease LY3954068, Placebo, Flortaucipir F18 - Alzheimer Disease | Phase 1 | Recruiting | Eli Lilly and Company | 56 | 2024-08-15 | 2026-10-29 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants VES001, Placebo - Dementia, Frontotemporal | Phase 1 | Completed | Vesper Biotechnologies ApS | 78 | 2023-10-11 | 2024-08-22 |
| A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Recruiting | AviadoBio Ltd | 18 | 2023-08-30 | 2026-08-13 |
| Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) WVE-004 10 mg Q12W - Amyotrophic Lateral Sclerosis, Frontotemporal Dementia | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 8 | 2022-12-14 | 2026-09-09 |
| The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia ET-STEM - Frontotemporal Dementia | Phase 1 | Active not recruiting | Samsung Medical Center | 12 | 2022-07-06 | 2024-02-21 |
| A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants APNmAb005, Placebo - Healthy Volunteers, Tauopathies | Phase 1 | Unknown | APRINOIA Therapeutics, LLC | 40 | 2022-05-06 | 2023-06-15 |
| Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology Verdiperstat - Semantic Dementia | Phase 1 | Active not recruiting | Peter Ljubenkov, MD | 64 | 2022-04-14 | 2026-07-06 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) DNL593, Placebo - Frontotemporal Dementia | Phase 1 / Phase 2 | Active not recruiting | Denali Therapeutics Inc. | 85 | 2022-02-01 | 2026-01-15 |
| First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia [18F]RP-115 PET/MRI or PET/CT and MRI - Alzheimer Disease, Frontotemporal Dementia | Phase 1 / Phase 2 | Recruiting | David Wilson | 102 | 2021-11-02 | 2025-04-17 |
| A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes PBFT02 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Terminated | Passage Bio, Inc. | 30 | 2021-09-14 | 2026-10-29 |
| Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy antisense oligonucleotide, placebo - Progressive Supranuclear Palsy (PSP) | Phase 1 | Completed | Novartis Pharmaceuticals | 59 | 2021-02-16 | 2025-12-24 |
| Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) LY3884963, Methylprednisolone, Optional Sirolimus - Frontotemporal Dementia | Phase 1 / Phase 2 | Active not recruiting | Prevail Therapeutics | 35 | 2020-11-09 | 2026-07-16 |
| Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease MemorEM - Alzheimer's Disease | Phase 1 / Phase 2 | Unknown | NeuroEM Therapeutics, Inc. | 6 | 2020-02-10 | 2020-02-17 |
| Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults 18F-MK-6240, 18F-Florbetaben - Alzheimer Disease | Phase 1 | Completed | Adam Brickman | 145 | 2019-03-22 | 2025-08-01 |
| A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation AL001, Placebo - Healthy, Frontotemporal Dementia | Phase 1 | Completed | Alector Inc. | 64 | 2018-09-14 | 2020-07-27 |
| BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES BIIB092, Placebo - Primary Tauopathies, Corticobasal Degeneration Syndrome | Phase 1 | Terminated | University of California, San Francisco | 22 | 2018-09-12 | 2019-12-19 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease IONIS MAPTRx, Placebo - Mild Alzheimer's Disease | Phase 1 | Completed | Ionis Pharmaceuticals, Inc. | 46 | 2017-10-12 | 2025-04-08 |
Showing 20 of 36. Sign in to see all of them.
Frontotemporal Dementia (21) · Pick Disease of the Brain (18) · Alzheimer Disease (11) · Dementia (7) · Aphasia, Primary Progressive (4) · Primary Progressive Nonfluent Aphasia (4) · Supranuclear Palsy, Progressive (4) · Tauopathies (4) · Cognitive Dysfunction (3) · Corticobasal Degeneration (2) · Nerve Degeneration (2) · Amyotrophic Lateral Sclerosis (1) · Aphasia (1) · Aphasia, Broca (1) · Apraxias (1)
Brain Diseases (35) · Central Nervous System Diseases (35) · Mental Disorders (35) · Nervous System Diseases (35) · Neurocognitive Disorders (35) · Neurodegenerative Diseases (31) · Dementia (29) · Metabolic Diseases (23) · Nutritional and Metabolic Diseases (23) · Proteostasis Deficiencies (23) · TDP-43 Proteinopathies (23) · Frontotemporal Dementia (15) · Pathological Conditions, Signs and Symptoms (14) · Tauopathies (11)
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (4) · AADvac1 (3) · 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (1) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · Lithium (1) · Magnetic Resonance Spectroscopy (1) · Methylprednisolone (1) · Oligonucleotides, Antisense (1) · Oxytocin (1) · THK5351 (1) · davunetide (1) · florbetapir (1) · gosuranemab (1)
Axon Neuroscience SE (3) · GAAD Medical Research Institute Inc. (2) · Mayo Clinic (2) · University of California, San Francisco (2) · APRINOIA Therapeutics, LLC (1) · Adam Brickman (1) · Alector Inc. (1) · Asan Foundation (1) · Assistance Publique - Hôpitaux de Paris (1) · AviadoBio Ltd (1) · Avid Radiopharmaceuticals (1) · David Wilson (1) · Denali Therapeutics Inc. (1) · Eli Lilly and Company (1) · Institute for Molecular Medicine (1)
United States (22) · United Kingdom (10) · Canada (8) · Netherlands (6) · Belgium (3) · France (3) · Germany (3) · Spain (3) · Australia (2) · Austria (2) · Brazil (2) · Italy (2) · Portugal (2) · South Korea (2) · Sweden (2)
Ken Nedd, M.D. (2) · Reinhold Schmidt, Professor (2) · Adam Boxer, MD, PhD (1) · Adam L. Boxer, M.D., Ph.D. (1) · Adam M. Brickman, Ph.D. (1) · Amy Berger, MD (1) · Danna Jennings, MD (1) · David Wilson, MD, PhD (1) · Elizabeth C Finger, MD (1) · George Stoica (1) · HeeJin Kim (1) · JaeEun Kim (1)
PMID 27955995, PMID 30355322, PMID 25478017, PMID 25503617, PMID 33141172, PMID 34815790, PMID 35260178, PMID 37095250, PMID 37322482, PMID 37624739, PMID 37902726, PMID 38594621, PMID 38745011, PMID 41389437, PMID 41673497, PMID 42875454
2016 (2), 2023 (2), 1RF1AG058067-01A1 (1), 2017 (1), R01AG073482 (1), R01AG092949 (1), R21NS094684 (1)